Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | MGTX |
---|---|---|
09:32 ET | 1544 | 4.2 |
09:34 ET | 100 | 4.22 |
09:36 ET | 3300 | 4.26 |
09:41 ET | 100 | 4.28 |
09:43 ET | 300 | 4.28 |
09:45 ET | 500 | 4.29 |
09:48 ET | 300 | 4.29 |
09:50 ET | 300 | 4.29 |
09:52 ET | 200 | 4.29 |
09:54 ET | 1289 | 4.24 |
09:56 ET | 1780 | 4.23 |
09:57 ET | 200 | 4.21 |
09:59 ET | 475 | 4.22 |
10:01 ET | 1654 | 4.19 |
10:06 ET | 100 | 4.15 |
10:08 ET | 100 | 4.18 |
10:14 ET | 200 | 4.16 |
10:15 ET | 100 | 4.17 |
10:17 ET | 400 | 4.18 |
10:19 ET | 200 | 4.18 |
10:21 ET | 100 | 4.18 |
10:24 ET | 2200 | 4.175 |
10:26 ET | 300 | 4.18 |
10:28 ET | 5900 | 4.1608 |
10:32 ET | 300 | 4.15 |
10:33 ET | 980 | 4.14 |
10:35 ET | 388 | 4.15 |
10:37 ET | 200 | 4.16 |
10:39 ET | 100 | 4.16 |
10:44 ET | 200 | 4.17 |
10:46 ET | 200 | 4.17 |
10:48 ET | 2310 | 4.14 |
10:50 ET | 100 | 4.12 |
10:53 ET | 100 | 4.12 |
10:55 ET | 2600 | 4.14 |
10:57 ET | 200 | 4.12 |
11:00 ET | 409 | 4.146 |
11:02 ET | 309 | 4.15 |
11:04 ET | 300 | 4.15 |
11:06 ET | 300 | 4.15 |
11:08 ET | 300 | 4.12 |
11:09 ET | 800 | 4.13 |
11:13 ET | 5032 | 4.145 |
11:15 ET | 300 | 4.14 |
11:18 ET | 2157 | 4.14 |
11:20 ET | 800 | 4.12 |
11:24 ET | 950 | 4.125 |
11:27 ET | 100 | 4.12 |
11:29 ET | 749 | 4.13 |
11:33 ET | 100 | 4.15 |
11:36 ET | 200 | 4.15 |
11:38 ET | 100 | 4.15 |
11:40 ET | 100 | 4.15 |
11:44 ET | 300 | 4.155 |
11:45 ET | 100 | 4.17 |
11:47 ET | 100 | 4.17 |
11:49 ET | 200 | 4.16 |
11:56 ET | 1390 | 4.16 |
11:58 ET | 1000 | 4.15 |
12:02 ET | 200 | 4.155 |
12:05 ET | 200 | 4.155 |
12:09 ET | 3214 | 4.17 |
12:12 ET | 100 | 4.16 |
12:14 ET | 100 | 4.16 |
12:16 ET | 100 | 4.16 |
12:18 ET | 100 | 4.17 |
12:23 ET | 100 | 4.175 |
12:30 ET | 100 | 4.18 |
12:32 ET | 100 | 4.17 |
12:34 ET | 100 | 4.18 |
12:36 ET | 2651 | 4.14 |
12:38 ET | 500 | 4.1386 |
12:41 ET | 700 | 4.13 |
12:43 ET | 100 | 4.12 |
12:48 ET | 100 | 4.11 |
12:50 ET | 700 | 4.11 |
12:56 ET | 2447 | 4.12 |
12:59 ET | 100 | 4.15 |
01:01 ET | 100 | 4.15 |
01:03 ET | 100 | 4.15 |
01:08 ET | 1200 | 4.12 |
01:10 ET | 100 | 4.13 |
01:17 ET | 2226 | 4.11 |
01:26 ET | 100 | 4.11 |
01:28 ET | 100 | 4.12 |
01:30 ET | 100 | 4.12 |
01:33 ET | 600 | 4.12 |
01:35 ET | 100 | 4.13 |
01:37 ET | 300 | 4.12 |
01:39 ET | 100 | 4.13 |
01:42 ET | 200 | 4.12 |
01:44 ET | 400 | 4.12 |
01:46 ET | 300 | 4.12 |
01:48 ET | 5039 | 4.13 |
01:50 ET | 6773 | 4.14 |
01:53 ET | 3837 | 4.16 |
02:00 ET | 200 | 4.17 |
02:02 ET | 100 | 4.17 |
02:09 ET | 100 | 4.18 |
02:15 ET | 100 | 4.17 |
02:20 ET | 100 | 4.18 |
02:22 ET | 100 | 4.17 |
02:26 ET | 300 | 4.17 |
02:27 ET | 200 | 4.175 |
02:29 ET | 200 | 4.18 |
02:33 ET | 2695 | 4.19 |
02:38 ET | 1400 | 4.17 |
02:45 ET | 744 | 4.165 |
02:49 ET | 100 | 4.17 |
02:51 ET | 200 | 4.16 |
02:58 ET | 200 | 4.17 |
03:00 ET | 416 | 4.18 |
03:05 ET | 200 | 4.18 |
03:07 ET | 1100 | 4.17 |
03:09 ET | 700 | 4.175 |
03:12 ET | 100 | 4.18 |
03:16 ET | 1190 | 4.17 |
03:18 ET | 200 | 4.17 |
03:21 ET | 700 | 4.16 |
03:30 ET | 100 | 4.17 |
03:32 ET | 100 | 4.17 |
03:34 ET | 300 | 4.17 |
03:36 ET | 200 | 4.17 |
03:38 ET | 300 | 4.17 |
03:39 ET | 100 | 4.17 |
03:41 ET | 200 | 4.16 |
03:43 ET | 200 | 4.17 |
03:48 ET | 400 | 4.17 |
03:50 ET | 200 | 4.17 |
03:52 ET | 463 | 4.17 |
03:54 ET | 500 | 4.17 |
03:56 ET | 3189 | 4.145 |
03:57 ET | 538 | 4.145 |
03:59 ET | 25946 | 4.16 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
MeiraGTx Holdings PLC | 321.9M | -2.8x | --- |
Iteos Therapeutics Inc | 372.9M | -3.3x | --- |
XOMA Royalty Corp | 309.9M | -12.2x | --- |
Ocugen Inc | 285.6M | -5.3x | --- |
Uniqure NV | 240.1M | -0.8x | --- |
Aldeyra Therapeutics Inc | 320.3M | -8.3x | --- |
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage gene therapy company. The Company is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. Its product pipeline includes botaretigene sparoparvovec or bota-vec, for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene or XLRP-RPGR; AAV-hAQP1 for the treatment of radiation-induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-asociated retinal dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia; AAV-AIPL1 for the treatment of LCA4, and AAV-RDH12 for the treatment of RDH12 mutation-associated retinal dystrophy.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $321.9M |
---|---|
Revenue (TTM) | $8.1M |
Shares Outstanding | 77.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.29 |
EPS | $-1.49 |
Book Value | $2.17 |
P/E Ratio | -2.8x |
Price/Sales (TTM) | 39.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2,083.19% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.